BSETransgene Biotek LtdCriticalNegative
Announced Mon, 1 Sept · 22:12 IST

General Intimation.

Sebi PenaltyNclt Insolvency AdmittedRegulatory & Legal View source PDFExplain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-5.1%1-day move
₹4.15
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-5.1-3.4-4.6-3.6-10.8-8.7-3.6+1.4-8.4-26.5
Up moveDown movePending
AI summary

Transgene Biotek has informed BSE that M/s Babaji Nethralayya Private Limited has initiated Corporate Insolvency Resolution Process (CIRP) against the company under Section 7 of the Insolvency and Bankruptcy Code, 2016. The trigger is an unpaid secured loan that the company had raised with board approval to clear urgent liabilities. The company blames its failure to repay on ongoing restrictions and penalties imposed by SEBI and the Enforcement Directorate. Appeals pending before the Securities Appellate Tribunal (SAT) in Mumbai and the Appellate Tribunal in Delhi have not yet been resolved. The company has stated it will try to settle with the creditor to prevent the matter from moving to the next stage of the insolvency process.

Likely market impact

This is materially negative for shareholders — initiation of CIRP typically leads to a sharp drop in stock price, possible trading suspension, and significant risk of equity value erosion or dilution under a resolution plan. Investors should brace for high volatility and monitor NCLT hearings closely.